Gilead Sciences acquires CymaBay Therapeutics for $4.3B

The latest stories trending on MedCity News.

Editor's Pick

Top Story Gilead's $4.3B CymaBay Acquisition Adds Liver Disease Drug Under FDA Review Acquiring CymaBay Therapeutics gives Gilead Sciences another drug for its liver disease portfolio. CymaBay's molecule, seladelpar, is under FDA review for treating primary biliary cholangitis, a rare disease affecting the bile ducts of the liver. Sponsored Content Lower BMI, Raise ROI: How Physician Practices Can Boost Revenues with a Turnkey Weight Management Program Presented by Build My Health and MedCity News The webinar, scheduled for March 6 at 2pm ET and sponsored by Build My Health, will discuss several topics related to weight management including: an overview of GLP-1 weight loss medication, automation in a subscription-based weight management program, and the rise of provider-to-consumer (PTC) models. Learn how to help patients lose weight as well as opportunity to generate $250K+ in monthly recurring revenue! 3 Days Left to Save $500 Whether you're looking for investors, a new partnership, innovative ideas, or just wanting to keep up with the latest trends and notable discussions, INVEST 2024 is the place to be to meet all your industry needs. You can save $500 until February 16th! Reserve Your Super Early Bird Seat Now

Featured News

FDA Reconsideration Leads to Approval of Takeda Drug for Rare Esophagus Disorder FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder. Who Needs To File With OHCA Under California's New Healthcare Transaction Regulations? Who do the California Office of Healthcare Affordability's cost and market impact review regulations apply to? That depends on three questions, according to a recent webinar. Views of Digital Health from the Oregon Trail Today, many hope artificial intelligence will be the key that unlocks the value of digitization. Perhaps it will, but the claim that better technology will necessarily improve healthcare is no longer credible. Having lived in both analog and digital worlds, who better than us Oregon Trail doctors to help ensure digital health technologies best serve our workforce, patients, and communities? Navigating the Challenges of Pediatric Surgery With Robotic-Assisted Procedures With the many advantages of robotics, it is time for pediatric patients to garner the same attention and technology development that adult patients have benefitted from for decades. How Access to Capital Benefits Radiology and Radiologists Private equity is a way to help achieve scale. Groups that use scale to better serve the stakeholders that matter most, including radiologists, hospitals, referring physicians and—most importantly—patients, will be best positioned to not just survive, but thrive. Unlocking the Potential of AI-Driven Biomarkers: A New Era in Personalized Cancer Care By leveraging AI and machine learning, researchers can analyze complex data sets, identify novel biomarkers, and provide more effective and tailored treatment options for cancer patients. Does Chronic Disease Management in Medicare Advantage Need a 'Retail' Makeover? Adopting consumer strategies from leading retailers can give MA plans an edge in an increasingly competitive market filled with new entities while improving quality, reducing cost, and improving member loyalty.

Resources

Recent Hires, Layoffs & an Interview with Kristin Myers, Chief Digital Officer at Northwell Health In this episode of The MedCity Moves Podcast, Senior Reporter Katie Adams chats with Kristin Myers, who recently became Northwell Health's first chief digital officer. Listen to learn more about Myers' career journey and what her goals are for her new organization. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe